MedTrace Logo

Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

NCT04493359 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-10-06

No results posted yet for this study

Summary

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

Conditions

  • Covid19
  • Angiotensin II Receptor Antagonist Adverse Reaction

Interventions

DRUG

Renin-angiotensin system inhibitors

switch anti-hypertensive class

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-25
Primary Completion
2021-09-28
Completion
2021-09-28

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04493359 on ClinicalTrials.gov